.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,422,119

« Back to Dashboard

Details for Patent: 5,422,119

Title: Transdermal hormone replacement therapy
Abstract:The present invention provides a method of treating a female in need of hormone replacement therapy comprising transdermally administering to said female a series of alternating phases of from about one to about four days of estrogen dominant activity and phases of from about one to about four days of progestin dominant activity, with the estrogen dominant activity phase consisting of administering a transdermal estrogen substance alone or administering a transdermal estrogen substance and a transdermal progestin substance and the progestin dominant activity phase consisting of administering a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
Inventor(s): Casper; Robert F. (Toronto, CA)
Assignee: Jencap Research Ltd. (Toronto, CA)
Filing Date:Jan 03, 1994
Application Number:08/177,355
Claims:1. A method of treating a female in need of hormone replacement therapy comprising transdermally administering to said female a pharmaceutical patch regimen series consisting essentially of a series of transdermal patches arranged in alternating phases of dominant hormone activity of from about one day to about four days, said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each of said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, said estrogen dominant activity phase consisting of administering a transdermal estrogen substance alone or administering a transdermal estrogen substance and a transdermal progestin substance, and said progestin dominant activity phase consisting of administering a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.

2. A method as claimed in claim 1 wherein each phase is administered by a single patch.

3. A method as claimed in claim 1 wherein each phase is administered by a plurality of patches.

4. A method as claimed in claim 1 wherein the estrogen and progestin are selected from estrogens and progestins which provide levels of activity, equivalent to a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day of 17-.beta. estradiol and from about 25 .mu.g/day to about 1000 .mu.g/day of norethindrone acetate or from about 5 .mu.g/day to about 150 .mu.g/day of 3-keto-desogestrel, with the proviso that the progestin is increased in the progestin dominant phase relative to the estrogen dominant phase to produce the required dominance.

5. A method as claimed in claim 1 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and the progestin dominant phase comprises an amount of 17-62 estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and an amount of norethindrone acetate sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 1000 .mu.g/day.

6. A method as claimed in claim 5 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

7. A method as claimed in claim 5 wherein the estrogen dominant phase comprises about four days and the progestin dominant phase comprises about three days.

8. A method as claimed in claim 5 wherein the amount of norethindrone acetate is sufficient to provide a transdermal delivery rate of from about 75 .mu.g/day to about 500 .mu.g/day.

9. A method as claimed in claim 5 wherein the amount of norethindrone acetate is sufficient to provide a transdermal delivery rate of from about 75 .mu.g/day to about 300 .mu.g/day.

10. A method as claimed in claim 1 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and an amount of 3-keto-desogestrel sufficient to provide a transdermal delivery rate of from about 5 .mu.g/day to about 150 .mu.g/day.

11. A method as claimed in claim 10 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

12. A method as claimed in claim 10 wherein the estrogen dominant phase comprises the equivalent of about four days and the progestin dominant phase comprises about three days.

13. A method as claimed in claim 10 wherein the amount of 3-keto-desogestrel is sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 150 .mu.g/day.

14. A method as claimed in claim 1 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and an amount of norethindrone acetate sufficient to provide a transdermal delivery rate of about 300 .mu.g/day.

15. A method as claimed in claim 14 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

16. A method as claimed in claim 14 wherein the estrogen dominant phase comprises about four days and the progestin dominant phase comprises about three days.

17. A method as claimed in claim 1 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and an amount of norethindrone acetate sufficient to provide a transdermal delivery rate of about 150 .mu.g/day.

18. A method as claimed in claim 17 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

19. A method as claimed in claim 17 wherein the estrogen dominant phase comprises about four days and the progestin dominant phase comprises about three days.

20. A pharmaceutical package comprising a transdermal patch regimen for administration to a female in need of hormone replacement therapy wherein the package comprises a pharmaceutical patch regimen series consisting essentially of a series of transdermal patches arranged in alternating phases of dominant hormone activity of from about one day to about four days, each of said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each of said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, said estrogen dominant activity phase consisting of a transdermal estrogen substance alone or a transdermal estrogen substance and a transdermal progestin substance, and said progestin dominant activity phase consisting of a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.

21. A package as claimed in claim 20 wherein the estrogen and progestin are selected from estrogens provide levels of activity equivalent to a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day of 17-.beta. estradiol and from about 25 .mu.g/day to about 1000 .mu.g/day of norethindrone acetate or from about 5 .mu.g/day to about 150 .mu.g/day of 3-keto-desogestrel, with the proviso that the progestin is increased in the progestin dominant phase relative to the estrogen dominant phase to produce the required dominance.

22. A package as claimed in claim 20 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and an amount of norethindrone acetate sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 1000 .mu.g/day.

23. A package as claimed in claim 22 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

24. A package as claimed in claim 22, wherein the estrogen dominant phase comprises about four days and the progestin dominant phase comprises about three days.

25. A package as claimed in claim 22 wherein the amount of norethindrone acetate is sufficient to provide a transdermal delivery rate of from about 75 .mu.g/day to about 500 .mu.g/day.

26. A package as claimed in claim 22 wherein the amount of norethindrone acetate is sufficient to provide a transdermal delivery rate of from about 75 .mu.g/day to about 300 .mu.g/day.

27. A package as claimed in claim 20 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 100 .mu.g/day and an amount of 3-keto-desogestrel sufficient to provide a transdermal delivery rate of from about 5 .mu.g/day to about 150 .mu.g/day.

28. A package as claimed in claim 27 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

29. A package as claimed in claim 27 wherein the estrogen dominant phase comprises the equivalent of about four days and the progestin dominant phase comprises the equivalent of about three days.

30. A package as claimed in claim 27 wherein the amount of 3-keto-desogestrel is sufficient to provide a transdermal delivery rate of from about 25 .mu.g/day to about 150 .mu.g/day.

31. A package as claimed in claim 20 wherein the estrogen dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and an amount of norethindrone acetate sufficient to provide a transdermal delivery rate of about 300 .mu.g/day.

32. A package as claimed in claim 31 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

33. A package as claimed in claim 31 wherein the estrogen dominant phase comprises about four days and the progestin dominant phase comprises about three days.

34. A package as claimed in claim 20 wherein the estrogen dominant phase comprises an amount of 17-62 estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and the progestin dominant phase comprises an amount of 17-.beta. estradiol sufficient to provide a transdermal delivery rate of about 50 .mu.g/day and an amount of norethindrone acetate sufficient to provide a transdermal delivery rate of about 150 .mu.g/day.

35. A package as claimed in claim 34 wherein the estrogen dominant phase comprises about three days and the progestin dominant phase comprises about four days.

36. A package as claimed in claim 34 wherein the estrogen dominant phase comprises about four days and the progestin dominant phase comprises about three days.

37. A package as claimed in claim 20 wherein each phase comprises a single patch.

38. A package as claimed in claim 20 wherein each phase comprises a plurality of patches.

39. A pharmaceutical preparation for administration to a female in need of hormone replacement therapy comprising a patch regimen series consisting essentially of a series of transdermal patches arranged in alternating phases of dominant hormone activity of from about one day to about four days, each of said phases being selected from estrogen dominant activity phases and progestin dominant activity phases, each of said phases comprising at least one patch which is applied and removed in accordance with the particular dominant phase activity, said estrogen dominant activity phase consisting of a transdermal estrogen substance alone or a transdermal estrogen substance and a transdermal progestin substance, and said progestin dominant activity phase consisting of a transdermal progestin substance and a transdermal estrogen substance, the amount of progestin substance being alternately increased in the progestin dominant activity phase and decreased in the estrogen dominant activity phase to provide the required dominant activity.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc